Response rate of patients with baseline brain metastases from recently diagnosed non‐small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status

Response rate of patients with baseline brain metastases from recently diagnosed non‐small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status

Abstract Background Previous studies have identified that patients with EGFR mutations tend to have better responses to targeted therapy, as well as chemotherapy; however, the effect of genetic alterations in terms of radiotherapy (RT)‐related outcomes has not been fully assessed. We studied the imp...

Full description

Bibliographic Details
Main Authors: Oscar Arrieta, Laura‐Alejandra Ramírez‐Tirado, Enrique Caballé‐Perez, Alberto Mejia‐Perez, Zyanya Lucia Zatarain‐Barrón, Andrés F. Cardona, Francisco Lozano‐Ruíz, Manuel Segura‐González, Graciela Cruz‐Rico, Federico Maldonado, Rafael Rosell
Format: Article
Language:English
Published: Wiley 2020-04-01
Series:Thoracic Cancer
Subjects:
EGFR
KRAS
radiosensitivity
radiotherapy
response rate
Online Access:https://doi.org/10.1111/1759-7714.13359

Internet

https://doi.org/10.1111/1759-7714.13359

Similar Items